Myasoedova, Elena http://orcid.org/0000-0003-2006-1436
Crowson, Cynthia S.
Giblon, Rachel E.
McCarthy-Fruin, Kathleen
Schaffer, Daniel E.
Wright, Kerry
Matteson, Eric L.
Davis, John M. III
Funding for this research was provided by:
Pfizer (Grant ID 15322005)
Article History
Received: 12 April 2019
Revised: 4 June 2019
Accepted: 25 June 2019
First Online: 1 July 2019
Compliance with ethical standards
: The study was approved by the Institutional Review Board of Mayo Clinic and was registered at the ClinicalTrials.gov Identifier: NCT02382783 (ExternalRef removed). All patients included in the study signed a written informed consent for participation in this study.
: Elena Myasoedova: no disclosures or COICynthia S. Crowson: no disclosures or COIRachel E. Giblon: no disclosures or COIKathleen McCarthy-Fruin: no disclosures or COIDaniel E. Schaffer: no disclosures or COIKerry Wright: no disclosures or COIEric L. Matteson: Grant/Research/Clinical Trial Support (rheumatoid arthritis)Genentech, Mesoblast, Novartis, Pfizer, Sun Pharmaceutical Industries, LtdEditorial functions: UpToDateJohn M. Davis, III: Grant/Research/Clinical Trial Support (rheumatoid arthritis) Pfizer
: Funders reviewed the protocol for the study but had no role in study conduct or interpretation of the results.